Clinical Pharmacology and Therapeutics 2004: Vol 75 Index

2004·3.4 MB·English

Author index*
A Cc
Abernethy DR. Paul Calabresi, 1930-2003. 2004;75:250-1 (Obituary) Cascorbi I (see Giessmann et al). 2004;75:213-22
Abernethy DR (see Urquidi-Macdonald et al). 2004;75:60-9 Cassar SC (see Katz et al). 2004;75:516-28
Ahmed SB (see Stelfox et al). 2004;75:1 10-22 Chen ST (see Huang et al). 2004;75:1-12 (Commentary)
Ahonen J (see Granfors et al). 2004;75:331-41 Chéne G (see Taburet et al). 2004;75:310-23
Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with Cheskin LJ (see Montoya et al). 2004;75:34-48
fluoroquinolones: importance of concomitant risk factors. 2004;75:242-7 Chi V (see McConnachie et al). 2004;75:282-97
Anglicheau D, Thervet E, Etienne I, De Ligny BH, Le Meur Y, Touchard G, Claes K (see Kuypers et al). 2004;75:434-47
Biichler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Clarke CL (see Wong et al). 2004;75:529-38
Marquet P. CYP3A5 and MDRI genetic polymorphisms and cyclosporine Clavel F (see Taburet et al). 2004;75:310-23
pharmacokinetics after renal transplantation. 2004;75:422-33 Coates PM (see Huang et al). 2004;75:1-12 (Commentary)
ANRS Protocol 104 (Puzzle 1) Investigatigators (see Taburet et al). 2004;75 Collins M (see Wong et al). 2004;75:529-38
310-23 Conemans J (see Schalekamp et al). 2004;75:394-402
Antikainen M (see Hedman et al). 2004;75:101-9 Contoreggi C (see Montoya et al). 2004;75:34-48
Aprelev A (see Rotter et al). 2004;75:248-9 (Letter) Currie G (see Sieber et al). 2004;75:70-9
B D
Baar C (see Duguay et al). 2004;75:223-33 Daly A (see Anglicheau et al). 2004;75:422-33
Backman JT (see Granfors et al). 2004;75:331-41 Daly AK (see Kamali et al). 2004;75:204-12
Badley AD (see Zhang et al). 2004;75:558-68 Dazert P (see Giessmann et al). 2004;75:213-22
Bajpai M (see McConnachie et al). 2004;75:282-97 de Boer A (see Schalekamp et al). 2004;75:394-402
Baker SD (see Engels et al). 2004;75:448-54 de Leon J (see Wedlund and de Leon). 2004;75:373-5 (Commentary)
Balleine RL (see Wong et al). 2004;75:529-38 De Ligny BH (see Anglicheau et al). 2004;75:422-33
Barone BB, Bunin GR. Folic acid and neuroblastoma: too soon to tell. 2004; De Martin S (see Orlando et al). 2004;75:80-8
75:489 (Letter) Deray G (see Izzedine et al). 2004;75:362-3 (Letter)
Barrail A (see Taburet et al). 2004;75:310-23 Desai M (see Gorski et al). 2004;75:89-100
Bart S (see Sieber et al). 2004;75:70-9 de Vries-Goldschmeding H (see Schalekamp et al). 2004;75:394-402
Bates DW (see Stelfox et al). 2004;75:110-22 Dishy V (see Sofowora et al). 2004;75:539-45
Bauer S (see Mwinyi et al). 2004;75:415-21 Dobrev D (see Schindler et al). 2004;75:49-59
Beaune P (see Anglicheau et al). 2004;75:422-33 Dorr A (see Zhang et al). 2004;75:558-68
Beaune PH (see Morin et al). 2004;75:403-14 Dragos D (see Rotter et al). 2004;75:248-9 (Letter)
Becquemont L (see Morin et al). 2004;75:403-14 Drenth JPH (see Simon et al). 2004;75:476-83
Beglinger C (see Sieber et al). 2004;75:70-9 Drewe E (see Simon et al). 2004;75:476-83
Benowitz NL (see Haller et al). 2004;75:259-73 Drewe J (see Sieber et al). 2004;75:70-9
Bernsen MJ (see Schalekamp et al). 2004;75:394-402 Drewelow B (see Mueller et al). 2004;75:546-57
Betz JM (see Huang et al). 2004;75:1-12 (Commentary) Driscoll RM (see Katz et al). 2004;75:516-28
Biaggioni I. Clinical and molecular pharmacologic characteristics of Droz C (see Taburet et al). 2004;75:310-23
adenosine-induced vasodilation. 2004;75:137-9 (Commentary) Dubert L (see Morin et al). 2004;75:403-14
Bijlstra P, van Ginneken EEM, Huls M, van Dijk R, Smits P, Rongen GA Duguay Y, Baar C, Skorpen F, Guillemette C. A novel functional polymor-
Glyburide inhibits dipyridamole-induced forearm vasodilation but not phism in the uridine diphosphate—glucuronosyltransferase 2B7 promoter
adenosine-induced forearm vasodilation. 2004;75:147-56 with significant impact on promoter activity. 2004;75:223-33
Birmingham BK (see Schneck et al). 2004;75:455-63
Bodin L (see Morin et al). 2004;75:403-14
Bodor M (see McConnachie et al}. 2004;75:282-97 E
Bondesson U (see Tannergren et al). 2004;75:298-309 Echizen H (see Takahashi et al). 2004;75:376-80 (Commentary)
Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with lefluno- Edholm M (see Gardmark et al). 2004;75:586-7 (Letter)
mide. 2004;75:580-5 Eichelbaum M (see von Richter et al). 2004;75:172-83
Briehl RW (see Rotter et al). 2004;75:248-9 (Letter) El-Aty AMA (see Wang et al). 2004;75:191-7
Brown CDA (see Schneck et al). 2004;75:455-63 Engel G (see Giessmann et al). 2004;75:213-22
Biichler M (see Anglicheau et al). 2004;75:422-33 Engels FK, ten Tije AJ, Baker SD, Lee CKK, Loos WJ, Vulto AG, Verweij J,
Buclin T (see Marzolini et al). 2004;75:13-33 Sparreboom A. Effect of cytochrome P450 3A4 inhibition on the pharma-
Bukofzer S (see Katz et al). 2004;75:516-28 cokinetics of docetaxel. 2004;75:448-54
Bull J (see Huang et al). 2004;75:1-12 (Commentary) Engman H (see Tannergren et al). 2004;75:298-309
Bunin GR (see Barone and Bunin). 2004;75:489 (Letter) Eschenhagen T (see Rau et al). 2004;75:386-93
Burk O (see von Richter et al). 2004;75:172-83 Esmay JD (see McConnachie et al). 2004;75:282-97
Byme DW (see Sofowora et al). 2004;75:539-45 Etienne I (see Anglicheau et al). 2004;75:422-33
Evenepoel P (see Kuypers et al). 2004;75:434-47
F
*January, pp. 1-136; February, pp. P1-P142; March, pp. 137-252; April, pp
253-372; May, pp. 373-490; June, pp. 491-602. Index to the ASCPT meeting Ferrone FA (see Rotter et al). 2004;75:248-9 (Letter)
abstracts is located in the February issue Fiskio J (see Stelfox et al). 2004;75:110-22
CLINICAL PHARMACOLOGY & THERAPEUTICS JUNE 2004 59]
CLINICAL PHARMACOLOGY & THERAPEUTICS
592 Author index JUNE 2004
Fitzgerald DJ (see Urquidi-Macdonald et al). 2004;75:60-9 Hiraoka H, Yamamoto K, Okano N, Morita T, Goto F, Horiuchi R. Changes in
Floreani M (see Orlando et al). 2004;75:80-8 drug plasma concentrations of an extensively bound and highly extracted
Francke K (see Schindler et al). 2004;75:49-59 drug, propofol, in response to altered plasma binding. 2004;75:324-30
Frank B (see Mueller et al). 2004;75:546-57 Ho RJY (see McConnachie et al). 2004;75:282-97
Frearson R (see Kamali et al). 2004;75:204-12 Hoffman FA (see Huang et al). 2004;75:1-12 (Commentary)
Frederick B (see Urquidi-Macdonald et al). 2004;75:60-9 Holmberg C (see Hedman et al). 2004;75:101-9
Freedman J (see Urquidi-Macdonald et al). 2004;75:60-9 Honig P (see Huang et al). 2004;75:1-12 (Commentary)
Fromm MF (see von Richter et al). 2004;75:172-83 Horiuchi R (see Hiraoka et al). 2004;75:324-30
Fudala PJ (see Montoya et al). 2004;75:34-48 Huang S-M, Hall SD, Watkins P, Love LA, Serabjit-Singh C, Betz JM,
Fuhr U (see Riessland et al). 2004;75:123-4 (Letter) Hoffman FA, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, Murray
Fujimoto Y (see Masuda et al). 2004;75:352-61 MD. Drug interactions with herbal products and grapefruit juice: a con-
Funck-Brentano C (see Morin et al). 2004;75:403-14 ference report. 2004;75:1-12 (Commentary)
Huang S-M (see Gorski et al). 2004;75:89-100
Hulot J-S (see Izzedine et al). 2004;75:362-3 (Letter)
G Huls M (see Bijlstra et al). 2004;75:147-56
Gaedigk A (see Kennedy et al). 2004;75:163-71. Correction 2004;75:579
Gardmark M, Edholm M, Ljungberg B. Pharmacokinetic studies in hepatic
impairment: is the Maddrey function a relevant marker? 2004;75:586-7
Ikeda Y, Umemura K, Kondo K, Sekiguchi K. Pharmacokinetics of voricon-
(Letter)
azole and cytochrome P450 2C19 genetic status. 2004;75:587-8 (Letter)
Gentile MC (see Katz et al). 2004;75:516-28
Gerloff T (see Mwinyi et al). 2004;75:415-21 Innocenti F, Ratain MJ. “Irinogenetics” and UGT/A: from genotypes to hap-
lotypes. 2004;75:495-500 (Commentary)
Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C,
Inui K-i (see Masuda et al). 2004;75:352-61
Warzok R, Engel G, Weitschies W, Cascorbi I, Kroemer HK, Siegmund
Izzedine H, Launay-Vacher V, Deray G, Hulot J-S. Nelfinavir and felodipine:
W. CYP2D6 genotype and induction of intestinal drug transporters by
a cytochrome P450 3A4—mediated drug interaction. 2004;75:362-3 (Let-
rifampin predict presystemic clearance of carvedilol in healthy subjects
2004;75:213-22 ter)
Girard P-M (see Taburet et al). 2004;75:
Gordon EF (see Katz et al). 2004;75:516-28 J
Gorelick DA (see Montoya et al). 2004;75:34-48
Gorski JC, Huang S-M, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai Jackson KA (see Hendrix et al). 2004;75:464-75
M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) Jacob P III (see Haller et al). 2004;75:259-73
on cytochrome P450 activity in vivo. 2004;75:89-100 Jacobson S (see Kopecky et al). 2004;75:140-6
Goto F (see Hiraoka et al). 2004;75:324-30 Jaillon P (see Morin et al). 2004;75:403-14
Goto M (see Masuda et al). 2004;75:352-61 Jinno H (see Sai et al). 2004;75:501-15
Graham DJ (see Bonnel and Graham). 2004;75:580-5 Johne A (see Mwinyi et al). 2004;75:415-21
Johnson RE (see Montoya et al). 2004;75:34-48
Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ. Fluvox-
Joshi P (see Kopecky et al). 2004;75:140-6
amine drastically increases concentrations and effects of tizanidine: a
Juntti-Patinen L (see Lilja et al). 2004;75:184-90
potentially hazardous interaction. 2004;75:331-41
Griffin MR, Stein CM, Ray WA. Postmarketing surveillance for drug safety:
surely we can do better. 2004;75:491-4 (Commentary)
K
Grimm DR (see Katz et al). 2004;75:516-28
Grossmann M (see Schindler et al). 2004;75:49-59 Kakar SM, Paine MF, Stewart PW, Watkins PB. 6'7’-Dihydroxybergamottin
Guidos A (see Hendrix et al). 2004;75:464-75 contributes to the grapefruit juice effect. 2004;75:569-79
Guillemette C (see Duguay et al). 2004;75:223-33 Kamakura S (see Sai et al). 2004;75:501-15
Gurney H (see Wong et al). 2004;75:529-38 Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK,
Wynne H. Contribution of age, body size, and CYP2C9 genotype to
Gustavson LE (see Katz et al). 2004;75:516-28
anticoagulant response to warfarin. 2004;75:204-12
Kamatani N (see Sai et al). 2004;75:501-15
Kang M-H (see Park et al). 2004;75 :157-62
Kaniwa N (see Sai et al). 2004;75:501-15
Hall K (see Ray et al). 2004;75:23 Kashuba ADM (see Kennedy et al). 2004;75:163-71. Correction 2004;75:579
Hall SD (see Gorski et al). 2004;75:89-100 Katori N (see Sai et al). 2004;75:501-15
Hall SD (see Huang et al). 2004;75:1-12 (Commentary) Katz DA, Grimm DR, Cassar SC, Gentile MC, Ye X, Rieser MJ, Gordon EF,
Haller CA, Jacob P III, Benowitz NL. Enhanced stimulant and metabolic Polzin JE, Gustavson LE, Driscoll RM, O’ Dea RF, Williams LA, Bukofzer
effects of combined ephedrine and caffeine. 2004;75:259-73 S. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma
Hamman MA (see Gorski et al). 2004;75:89-100 levels. 2004;75:516-28
Hasegawa R (see Sai et al). 2004;75:501-15 Kearns GL (see Huang et al). 2004;75:1-12 (Commentary)
Hecker U (see Giessmann et al). 2004;75:213-22 Kearns GL (see Kennedy et al). 2004;75:163-71. Correction 2004;75:579
Hedeland M (see Tannergren et al). 2004;75:298-309 Kelley RI (see Simon et al). 2004;75:476-83
Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Phar- Kennedy MJ, Scripture CD, Kashuba ADM, Scott CS, Gaedigk A, Kearns GL.
macokinetics and pharmacodynamics of pravastatin in pediatric and ado- Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxi-
lescent cardiac transplant recipients on a regimen of triple immunosup- dase, and cytochrome P450 2D6 are unaltered in children with cystic
pression. 2004;75:101-9 fibrosis. 2004;75:163-71. Correction 2004;75:579
Hehl E-M (see Mueller et al). 2004;75:546-57 Kesteven P (see Kamali et al). 2004;75:204-12
Hendrix CW, Jackson KA, Whitmore E, Guidos A, Kretzer R, Liss CM, Shah Khan TI (see Kamali et al). 2004;75:204-12
LP, Khoo K-C, McLane J, Trapnell CB. The effect of isotretinoin on the Khoo K-C (see Hendrix et al). 2004;75:464-75
pharmacokinetics and pharmacodynamics of ethinyl estradiol and noreth Kim K-A (see Park et al). 2004;75:157-62
indrone. 2004;75:464-75 Kim RB. 3-Hydroxy-3-methylglutaryl-coenzyme A_ reductase inhibitors
Hilligoss JK (see Gorski et al). 2004;75:89-100 (statins) and genetic variability (single nucleotide polymorphisms) in a
CLINICAL PHARMACOLOGY & THERAPEUTICS
2004;75(6):591-5 Author index 593
hepatic drug uptake transporter: what’s it all about? 2004;75:381-5 (Com- Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR/
mentary) (P-glycoprotein): recent advances and clinical relevance. 2004;75:13-33
Kim RB (see Marzolini et al). 2004;75:1: Mascelli MA (see Urquidi-Macdonald et al). 2004;75:60-9
Kim RB (see Sofowora et al). 2004;75:5: Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, Inui K-i. Tacrolimus
Kim S-L (see Park et al). 2004;75:157-62 therapy according to mucosal MDR1 levels in small-bowel transplant
Kinchelow T (see Zhang et al). 2004;75:558-68 recipients. 2004;75:352-61
King BP (see Kamali et al). 2004;75:204-12 McConnachie L, Bodor M, Kowdley K, Levy A, Tung B, Thummel K, Phillips
Kirch W (see Schindler et al). 2004;75:49-59 B, Bajpai M, Chi V, Esmay JD, Shen DD, Ho RJY. Human liver cyto-
Kitakaze M (see Sai et al). 2004;75:501-15 chrome P450 2D6 genotype, full-length messenger ribonucleic acid, and
Kitamura Y (see Sai et al). 2004;75:501-15 activity assessed with a novel cytochrome P450 2D6 substrate. 2004;75
Kivist6 KT (see von Richter et al). 2004;75:172-83 282-97
Kleiman NS (see Urquidi-Macdonald et al). 2004;75:60-9 McLane J (see Hendrix et al). 2004;75:464-75
Knutson L (see Tannergren et al). 2004;75:298-309 Meredith S (see Ray et al). 2004;75:234-41
Kolis SJ (see Zhang et al). 2004;75:558-68 Miller M (see Gorski et al). 2004;75:89-100
Komamura K (see Sai et al). 2004;75:501-15 Minami H (see Sai et al). 2004;75:501-15
Kondo K (see Ikeda et al). 2004;75:587-8 (Letter) Mitchell PD (see Schneck et al). 2004;75:455-63
Kopecky EA, Jacobson S, Joshi P, Koren G. Systemic exposure to morphine Modess C (see Giessmann et al). 2004;75:213-22
and the risk of acute chest syndrome in sickle cell disease. 2004;75:140-6 Moia M (see Peyvandi et al). 2004;75:198-203
Koren G. Folic acid and neuroblastoma: too soon to tell. 2004;75:490 (Letter Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin
reply) LJ, Lange R, Contoreggi C, Johnson RE, Fudala PJ. Randomized trial of
Koren G (see Kopecky et al). 2004;75:140-6 buprenorphine for treatment of concurrent opiate and cocaine dependence
Kowdley K (see McConnachie et al). 2004;75:282-97 2004;75:34-48
Kretzer R (see Hendrix et al). 2004;75:464-75 Morand-Joubert L (see Taburet et al). 2004;75:310-23
Krishnan SC (see Amankwa et al). 2004;75:242-7 Morin S, Bodin L, Loriot M-A, Thijssen HHW, Robert A, Strabach S, Ver-
Kroemer HK (see Giessmann et al). 2004;75:213-22 stuyft C, Tregouet D-A, Dubert L, Laurent-Pvig P, Funck-Brentano C
Kunert-Keil C (see Giessmann et al). 2004;75:213-22 Jaillon P, Beaune PH, Becquemont L. Pharmacogenetics of acenocoumarol
Kuypers DRJ, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical pharmacodynamics. 2004;75:403-14
efficacy and toxicity profile of tacrolimus and mycophenolic acid in rela- Morita T (see Hiraoka et al). 2004;75:324-30
tion to combined long-term pharmacokinetics in de novo renal allograft Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl
recipients. 2004;75:434-47 E-M, Sievers H, Frank B, Riethling A-K, Drewelow B. Effect of St John’s
Kwong S (see Rotter et al). 2004;75:248-9 (Letter) wort dose and preparations on the pharmacokinetics of digoxin. 2004;75
546-57
Murray KT (see Ray et al). 2004;75:234-41
Murray MD (see Huang et al). 2004;75:1-12 (Commentary)
Lalezari JP (see Zhang et al). 2004;75:558-68 Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects
Lanczik M (see Rau et al). 2004;75:386-93 of OATP-C (SLC21A6) *5 and */b haplotypes on pravastatin kinetics
Landau R (see Sofowora et al). 2004;75:539-45 2004;75:415-21
Lange R (see Montoya et al). 2004;75:
Larsen F (see Sieber et al). 2004;7
Lasseter KC (see Schneck et al) N
362-3 (Letter)
Neuvonen M (see Granfors et al). 2004;75:331-41
Laurent-Puig P (see Anglicheau et al). 2004;75:422-33
Neuvonen M (see Hedman et al). 2004;75:101-9
Laurent-Puig P (see Morin et al). 2004;75:403-14
Neuvonen PJ (see Granfors et al). 2004;75:331-41
Lee CKK (see Engels et al). 2004;75:448-54 Neuvonen PJ (see Hedman et al). 2004;75:101-9
Legendre C (see Anglicheau et al). 2004;75:422-33
Neuvonen PJ (see Lilja et al). 2004;75:184-90
Le Meur Y (see Anglicheau et al). 2004;75:422-33
Nygaard U, Toft N, Schmiegelow K. Methylated metabolites
Lennernis H (see Tannergren et al). 2004;75:298-309
6-mercaptopurine are associated with hepatotoxicity. 2004;75:274-81
Le Tiec C (see Taburet et al). 2004;75:310-23
Levy A (see McConnachie et al). 2004;75
Li T (see Wang et al). 2004;75:191-7 O
Liddle C (see Wong et al). 2004;75:529-38
O'Dea RF (see Katz et al). 2004;75:516-28
Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the
Ohtsu A (see Sai et al). 2004;75:501-15
bioavailability of the B-adrenergic—blocking agent celiprolol. 2004;75
184-90 Okano N (see Hiraoka et al). 2004;75:324-30
Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Cyto-
Liss CM (see Hendrix et al). 2004;75:464-75
Liu J (see Wang et al). 2004;75:191-7 chrome P450 1A2 is a major determinant of lidocaine metabolism in vivo
Ljungberg B (see Gardmark et al). 2004;75:586-7 (Letter) effects of liver function. 2004;75:80-8
Ozawa §S (see Sai et al). 2004;75:501-15
Loos WJ (see Engels et al). 2004;75:448-54
Loriot M-A (see Morin et al). 2004;75:403-14
Love LA (see Huang et al). 2004;75:1-12 (Commentary) P
Lunkenheimer J (see Rau et al). 2004;75:386-93
Padrini R (see Orlando et al). 2004;75:80-8
Padrini R (see Takahashi et al). 2004;75:376-80 (Commentary)
M Paine MF (see Kakar et al). 2004;75:569-79
Maes B (see Kuypers et al). 2004;75:434-47 Palatini P (see Orlando et al). 2004;75:80-8
Mager DE (see Urquidi-Macdonald et al). 2004;75:60-9 Park J-Y, Kim K-A, Kang M-H, Kim S-L, Shin J-G. Effect of rifampin on the
Majcher-Peszynska J (see Mueller et al). 2004;75:546-57 pharmacokinetics of rosiglitazone in healthy subjects. 2004;75:157-62
Mannucci PM (see Peyvandi et al). 2004;75:198-203 Patel IH (see Zhang et al). 2004;75:558-68
Marquet P (see Anglicheau et al). 2004;75:422-33 Paus E (see Marzolini et al). 2004;75:13-33
Martin PD (see Schneck et al). 2004;75:455-63 Petzsch M (see Mueller et al). 2004;75:546-57
CLINICAL PHARMACOLOGY & THERAPEUTICS
594 Author index JUNE 2004
Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM. CYP2C9 Shah LP (see Hendrix et al). 2004;75:464-75
genotypes and dose requirements during the induction phase of oral anti- Shen DD (see McConnachie et al). 2004;75:282-97
coagulant therapy. 2004;75:198-203 Shin J-G (see Park et al). 2004;75:157-62
Phillips B (see McConnachie et al). 2004;75:282-97 Shirao K (see Sai et al). 2004;75:501-15
Piccoli P (see Orlando et al). 2004;75:80-8 Siboni SM (see Peyvandi et al). 2004;75:198-203
Pinto A (see Gorski et al). 2004;75:89-100 Sieber CC, Beglinger C, Bart S, Tschoepl M, Currie G, Larsen F, Drewe J.
Pittrow D (see Schindler et al). 2004;75:49-59 Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the
Pollak PT, Shafer SL. Use of population modeling to define rational monitoring rate of infusion. 2004;75:70-9
of amiodarone hepatic effects. 2004;75:342-51 Siegler EL, Reidenberg M. Treatment of urinary incontinence with anticholin-
Polzin JE (see Katz et al). 2004;75:516-28 ergics in patients taking cholinesterase inhibitors for dementia. 2004;75:
Powell RJ (see Simon et al). 2004;75:476-83
484-8
Prasad HC (see Sofowora et al). 2004;75:539-45 Siegmund W (see Giessmann et al). 2004;75:213-22
Preston KL (see Montoya et al). 2004;75:34-48 Sievers H (see Mueller et al). 2004;75:546-57
Punwani NG. Tramadol pharmacokinetics and its possible interactions with
Simon A, Drewe E, van der Meer JWM, Powell RJ, Kelley RI, Stalenhoef
cyclooxygenase 2-selective nonsteroidal anti-inflammatory drugs. 2004;
AFH, Drenth JPH. Simvastatin treatment for inflammatory attacks of the
75:363-5 (Letter) hyperimmunoglobulinemia D and periodic fever syndrome. 2004;75:
476-83
R Skorpen F (see Duguay et al). 2004;75:223-33
Raguin G (see Taburet et al). 2004;75:310-23 Smiley RM (see Sofowora et al). 2004;75:539-45
Ratain MJ (see Innocenti and Ratain). 2004;75:495-500 (Commentary) Smits P (see Bijlstra et al). 2004;75:147-56
Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Sofowora GG, Dishy V, Landau R, Xie H-G, Prasad HC, Byrne DW, Smiley
Eschenhagen T. CYP2D6 genotype: impact on adverse effects and nonre- RM, Kim RB, Wood AJJ, Stein CM. a,,-Adrenergic receptor polymor-
sponse during treatment with antidepressants—a pilot study. 2004;75: phism and vascular response. 2004;75:539-45
386-93 Sparreboom A (see Engels et al). 2004;75:448-54
Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants Spreafico M (see Peyvandi et al). 2004;75:198-203
and the risk of sudden cardiac death. 2004;75:234-41 Stalenhoef AFH (see Simon et al). 2004;75:476-83
Ray WA (see Griffin et al). 2004;75:491-4 (Commentary) Stein CM (see Griffin et al). 2004;75:491-4 (Commentary)
Raza A (see Schneck et al). 2004;75:455-63 Stein CM (see Sofowora et al). 2004;75:539-45
Reidenberg M (see Siegler and Reidenberg). 2004;75:484-8 Stelfox HT, Ahmed SB, Fiskio J, Bates DW. Monitoring amiodarone’s toxic-
Rieser MJ (see Katz et al). 2004;75:516-28 ities: recommendations, evidence, and clinical practice. 2004;75:110-22
Riessland M, Tomalik-Scharte D, Fuhr U. Do data presented at an American Stewart PW (see Kakar et al). 2004;75:569-79
Society for Clinical Pharmacology and Therapeutics meeting make it to Strabach S (see Morin et al). 2004;75:403-14
full publication? 2004;75:123-4 (Letter) Sullivan JT. A message from the ASCPT Membership Committee Chairperson.
Riethling A-K (see Mueller et al). 2004;75:546-57 2004;75:252
Robert A (see Morin et al). 2004;75:403-14
Sullivan JT. A message from the ASCPT Membership Committee Chairperson.
Rongen GA (see Bijlstra et al). 2004;75:147-56 2004;75:371-2
Roots I (see Mwinyi et al). 2004;75:415-21
Rotter MA, Aprelev A, Dragos D, Ferrone FA, Kwong S, Briehl RW. Aspar-
tame has no effect on the polymerization of sickle hemoglobin. 2004;75 T
248-9 (Letter)
Taburet A-M, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-
Joubert L, Chéne G, Clavel F, Girard P-M, ANRS Protocol 104 (Puzzle 1)
S
Investigators. Interactions between amprenavir and the lopinavir-ritonavir
Saeki M (see Sai et al). 2004;75:501-15 combination in heavily pretreated patients infected with human immuno-
Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, deficiency virus. 2004;75:310-23
Sawada J-i, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Takahashi H, Wilkinson GR, Padrini R, Echizen H. CYP2C9 and oral antico-
Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T, Saijo N. UGT/A/ agulation therapy with acenocoumarol and warfarin: similarities yet dif-
haplotypes associated with reduced glucuronidation and increased serum ferences. 2004;75:376-80 (Commentary)
bilirubin in irinotecan-administered Japanese patients with cancer. 2004; Tanaka K (see Masuda et al). 2004;75:352-61
75:501-15
Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas
Saijo N (see Sai et al). 2004;75:501-15
H. St John’s wort decreases the bioavailability of R- and S-verapamil
Saito Y (see Sai et al). 2004;75:S01-15
through induction of the first-pass metabolism. 2004;75:298-309
Sawada J-i (see Sai et al). 2004;75:501-15
ten Tije AJ (see Engels et al). 2004;75:448-54
Schalekamp T, van Geest-Daalderop JHH, de Vries-Goldschmeding H, Cone-
Thapa PB (see Ray et al). 2004;75:234-41
mans J, Bernsen MJ, de Boer A. Acenocoumarol stabilization is delayed in
CYP2C9*3 carriers. 2004;75:394-402 Thervet E (see Anglicheau et al). 2004;75:422-33
Schindler C, Dobrev D, Grossmann M, Francke K, Pittrow D, Kirch W. Thijssen HHW (see Morin et al). 2004;75:403-14
Mechanisms of B-adrenergic receptor--mediated venodilation in humans Thon KP (see von Richter et al). 2004;75:172-83
2004;75:49-59 Thuerauf N (see Rau et al). 2004;75:386-93
Schmiegelow K (see Nygaard et al). 2004;75:274-81 Thummel K (see McConnachie et al). 2004;75:282-97
Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin Tisdale JE (see Amankwa et al). 2004;75:242-7
PD, Lasseter KC, Brown CDA, Windass AS, Raza A. The effect of Toft N (see Nygaard et al). 2004;75:274-81
gemfibrozil on the pharmacokinetics of rosuvastatin. 2004;75:455-63 Tomalik-Scharte D (see Riessland et al). 2004;75:123-4 (Letter)
Schroeder JR (see Montoya et al). 2004;75:34-48 Touchard G (see Anglicheau et al). 2004;75:422-33
Scott CS (see Kennedy et al). 2004;75:163-71. Correction 2004;75:579 Trapnell CB (see Hendrix et al). 2004;75:464-75
Scripture CD (see Kennedy et al). 2004;75:163-71. Correction 2004;75:579 Tregouet D (see Anglicheau et al). 2004;75:422-33
Sekiguchi K (see Ikeda et al). 2004;75:587-8 (Letter) Tregouet D-A (see Morin et al). 2004;75:403-14
Serabjit-Singh C (see Huang et al). 2004;75:1-12 (Commentary) Tschoepl M (see Sieber et al). 2004;75:70-9
Shafer SL (see Pollak and Shafer). 2004;75:342-51 Tung B (see McConnachie et al). 2004;75:282-97
CLINICAL PHARMACOLOGY & THERAPEUTICS
2004;75(6):591-5 Author index 595
U Weinshilboum R, Wang L. Pharmacogenetics: inherited variation in amino acid
Uehleke B (see Mueller et al). 2004;75:546-57 sequence and altered protein quantity. 2004;75:253-8 (Commentary)
Uemoto S (see Masuda et al). 2004;75:352-61 Weitschies W (see Giessmann et al). 2004;75:213-22
Ueno K( see Sai et al). 2004;75:501-15 Whitmore E (see Hendrix et al). 2004;75:464-75
Umbricht A (see Montoya et al). 2004;75:34-48 Wilkinson GR (see Takahashi et al). 2004;75:376-80 (Commentary)
Umemura K (see Ikeda et al). 2004;75:587-8 (Letter) Williams LA (see Katz et al). 2004;75:516-28
Urquidi-Macdonald M, Mager DE, Mascelli MA, Frederick B, Freedman J, Windass AS (see Schneck et al). 2004;75:455-63
Fitzgerald DJ, Kleiman NS, Abernethy DR. Abciximab pharmacodynamic Woehling H (see Mueller et al). 2004;75:546-57
model with neural networks used to integrate sources of patient variability. Wohlleben G (see Rau et al). 2004;75:386-93
2004;75:60-9 Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5
genotype and midazolam clearance in Australian patients receiving che-
V motherapy. 2004;75:529-38
Wood AJJ (see Sofowora et al). 2004;75:539-45
van der Meer JWM (see Simon et al). 2004;75:476-83 Wood P (see Kamali et al). 2004;75:204-12
van Dijk R (see Bijlstra et al). 2004;75:147-56 Wu J (see Wang et al). 2004;75:191-7
van Geest-Daalderop JHH (see Schalekamp et al). 2004;75:394-402 Wuttke H (see Rau et al). 2004;75:386-93
van Ginneken EEM (see Bijlstra et al). 2004;75:147-56 Wynne H (see Kamali et al). 2004;75:204-12
Vanrenterghem Y (see Kuypers et al). 2004;75:434-47
Verstuyft C (see Morin et al). 2004;75:403-14
Verweij J (see Engels et al). 2004;75:448-54 X
Vincent I (see Taburet et al). 2004;75:310-23 Xie H-G (see Sofowora et al). 2004;75:539-45
von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivist6 KT
Cytochrome P450 3A4 and P-glycoprotein expression in human small
intestinal enterocytes and hepatocytes: a comparative analysis in paired Y
tissue specimens. 2004;75:172-83
Yamamoto K (see Hiraoka et al). 2004;75:324-30
Vulto AG (see Engels et al). 2004;75:448-54
Yang T-L (see Wang et al). 2004;75:191-7
Ye X (see Katz et al). 2004;75:516-28
Ww Yoshida T (see Sai et al). 2004;75:501-15
Wang D (see Wang et al). 2004;75:191-7
Wang J-G (see Wang et al). 2004;75:191-7
Wang L( see Weinshilboum and Wang). 2004;75:253-8 (Commentary) Z
Wang L-S, Zhou G, Zhu B, Wu J, Wang J-G, El-Aty AMA, Li T, Liu J, Yang Zaheer NA (see Gorski et al). 2004;75:89-100
T-L, Wang D, Zhong X-Y, Zhou H-H. St John’s wort induces both Zalikowski JA (see Schneck et al). 2004;75:455-63
cytochrome P450 3A4-catalyzed sulfoxidation and 2C19—dependent hy- Zhang X, Lalezari JP, Badley AD, Dorr A, Kolis SJ, Kinchelow T, Patel IH
droxylation of omeprazole. 2004;75:191-7 Assessment of drug-drug interaction potential of enfuvirtide in human
Wang Y (see Schneck et al). 2004;75:455-63 immunodeficiency virus type |—infected patients. 2004;75:558-68
Warzok R (see Giessmann et al). 2004;75:213-22 Zhong X-Y (see Wang et al). 2004;75:191-7
Watkins P (see Huang et al). 2004;75:1-12 (Commentary) Zhou G (see Wang et al). 2004;75:191-7
Watkins PB (see Kakar et al). 2004;75:569-79 Zhou H-H (see Wang et al). 2004;75:191-7
Wedlund PJ, de Leon J. Cytochrome P450 2D6 and antidepressant toxicity and Zhu B (see Wang et al). 2004;75:191-7
response: what is the evidence? 2004;75:373-5 (Commentary) Zschiesche M (see Giessmann et al). 2004;75:213-22
Subject index*
A message from the ASCPT Membership Committee Chairperson (Sulli-
van). 2004;75:252
Abciximab
A message from the ASCPT Membership Committee Chairperson (Sulli-
Abciximab pharmacodynamic model with neural networks used to inte-
van). 2004;75:371-2
grate sources of patient variability (Urquidi-Macdonald et al). 2004;
Amino acid sequence
Pharmacogenetics: inherited variation in amino acid sequence and altered
Abstracts
protein quantity (Weinshilboum and Wang). 2004;75:253-8 (Commen-
Abstracts. 2004;75:P1-142
ABT-773 tary)
Amiodarone
CYP3AS genotype has a dose-dependent effect on ABT-773 plasma levels
Monitoring amiodarone’s toxicities: recommendations, evidence, and clin-
(Katz et al). 2004;75:516-28
ical practice (Stelfox et al). 2004;75:110-22
Acenocoumarol
Use of population modeling to define rational monitoring of amiodarone
Acenocoumarol stabilization is delayed in CYP2C9*3 carriers (Schale-
hepatic effects (Pollak and Shafer). 2004;75:342-51
kamp et al). 2004;75:394-402
Amprenavir
CYP2C¢9 and oral anticoagulation therapy with acenocoumarol and warfa-
Interactions between amprenavir and the lopinavir-ritonavir combination in
rin: similarities yet differences (Takahashi et al). 2004;75:376-80
heavily pretreated patients infected with human immunodeficiency
(Commentary)
virus (Taburet et al). 2004;75:310-23
Pharmacogenetics of acenocoumarol pharmacodynamics (Morin et al).
Anemia, sickle cell
2004;75:403-14
Systemic exposure to morphine and the risk of acute chest syndrome in
Acetyltransferases
sickle cell disease (Kopecky et al). 2004;75:140-6
Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxi-
Anions
dase, and cytochrome P450 2D6 are unaltered in children with cystic
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin (Schneck
fibrosis (Kennedy et al). 2004;75:163-71. Correction 2004;75:579
et al). 2004;75:455-63
Acute chest syndrome; see Thorax
Evidence for inverse effects of OATP-C (SLC21A6) *5 and */b haplotypes
Adenosine
on pravastatin kinetics (Mwinyi et al). 2004;75:415-21
Clinical and molecular pharmacologic characteristics of adenosine-induced
Anti-infective agents, fluoroquinolone
vasodilation (Biaggioni). 2004;75:137-9 (Commentary)
Torsades de pointes associated with fluoroquinolones: importance of con-
Glyburide inhibits dipyridamole-induced forearm vasodilation but not
comitant risk factors (Amankwa et al). 2004;75:242-7
adenosine-induced forearm vasodilation (Bijlstra et al). 2004;75:
Anti-inflammatory agents, non-steroidal
147-56
Tramadol pharmacokinetics and its possible interactions with cyclooxy-
Administration, oral
genase 2-selective nonsteroidal anti-inflammatory drugs (Punwani).
Acenocoumarol stabilization is delayed in CYP2C9*3 carriers (Schale-
2004;75:363-5 (Letter)
kamp et al). 2004;75:394-402
Antibiotics
CYP2C9 genotypes and dose requirements during the induction phase of CYP3AS genotype has a dose-dependent effect on ABT-7747352 plasma levels
oral anticoagulant therapy (Peyvandi et al). 2004;75:198-203
(Katz et al). 2004;75:516-28
CYP2C49 and oral anticoagulation therapy with acenocoumaro] and warfa-
Anticholinergics; see Parasympatholytics
rin: similarities yet differences (Takahashi et al). 2004;75:376-80
Anticoagulants
(Commentary) Acenocoumarol stabilization is delayed in CYP2C9*3 2 carriers (Schale-
Administration and dosage
kamp et al). 2004;75:394-402
CYP2C9 genotypes and dose requirements during the induction phase of
Contribution of age, body size, and CYP2C9 genotype to anticoagulant
oral anticoagulant therapy (Peyvandi et al). 2004;75: 198-203
response to warfarin (Kamali et al). 2004;75:204-12
Adolescence
CYP2C9 genotypes and dose requirements during the induction phase of
Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and
oral anticoagulant therapy (Peyvandi et al). 2004;75:198-203
adolescent cardiac transplant recipients on a regimen of triple immu-
CYP2C¢9 and oral anticoagulation therapy with acenocoumarol and warfa-
nosuppression (Hedman et al). 2004;75:101-9
rin: similarities yet differences (Takahashi et al). 2004;75:376-80
Adrenergic beta receptor blockaders
(Commentary)
Orange juice substantially reduces the bioavailability of the B-adrenergic
Pharmacogenetics of acenocoumarol pharmacodynamics (Morin et al).
blocking agent celiprolol (Lilja et al). 2004;75:184-90
2004;75:403-14
Age factors
Antidepressive agents
Contribution of age, body size, and CYP2C9 genotype to anticoagulant
Cyclic antidepressants and the risk of sudden cardiac death (Ray et al).
response to warfarin (Kamali et al). 2004;75:204-12
2004;75:234-41
Allograft; see Transplantation, homologous
CYP2D6 genotype: impact on adverse effects and nonresponse during
Alpha adrenergic receptors; see Receptors. adrenergic, alpha
treatment with antidepressants—a pilot study (Rau et al). 2004
Alternative medicine
386-93
St John’s wort induces both cytochrome P450 3A4—catalyzed sulfoxida-
Cytochrome P450 2D6 and antidepressant toxicity and response: what is
tion and 2C19—dependent hydroxylation of omeprazole (Wang et al).
the evidence? (Wedlund and de Leon). 2004;75:373-5 (Commentary)
2004;75:191-7
Antineoplastic agents
American Society for Clinical Pharmacology and Therapeutics
Effect of cytochrome P450 3A4 inhibitiGn on the pharmacokinetics of
Do data presented at an American Society for Clinical Pharmacology and
docetaxel (Engels et al). 2004;75:448-54
Therapeutics meeting make it to full publication? (Riessland et al).
Arthritis, rheumatoid
2004;75:123-4 (Letter)
Peripheral neuropathy in patients treated with leflunomide (Bonnel and
Graham). 2004;75:580-5
January, pp. 1-136; February, pp. P1-P142; March, pp. 137-252; Aspartame
April, pp. 253-372; May, pp. 373-490; June, pp. 491-602. Index to Aspartame has no effect on the polymerization of sickle hemoglobin
the ASCPT meeting abstracts is located in the February issue. (Rotter et al). 2004;75:248-9 (Letter)
596 JUNE 2004 CLINICAL PHARMACOLOGY & THERAPEUTICS
CLINICAL PHARMACOLOGY & THERAPEUTICS
Subject index 597
2004;75(6):596-602
Australia Cholinesterase inhibitors
CYP3A5 genotype and midazolam clearance in Australian patients receiv Treatment of urinary incontinence with anticholinergics in patients taking
ing chemotherapy (Wong et al). 2004;75:5 29-38 cholinesterase inhibitors for dementia (Siegler and Reidenberg). 2004
75:484-8
B Cocaine
Beta adrenergic blocking agents; see Adrenergic beta receptor blockaders Randomized trial of buprenorphine for treatment of concurrent opiate and
Beta adrenergic receptors; see Receptors, adrenergic, beta cocaine dependence (Montoya et al). 2004;75:34-48
Beverages Coenzyme A
6’7’-Dihydroxybergamottin contributes to the grapefruit juice effect 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)
(Kakar et al). 2004;75:569-79 and genetic variability (single nucleotide polymorphisms) in a hepatic
Drug interactions with herbal products and grapefruit juice: a conference drug uptake transporter: what's it all about? (Kim). 2004;75:381-5
report (Huang et al). 2004;75:1-12 (Commentary) (Commentary)
Orange juice substantially reduces the bioavailability of the B-adrenergic Commentaries
blocking agent celiprolol (Lilja et al). 2004;75:184-90 Commentaries. 2004;75:1-12, 137-9, 253-8, 373-85, 491-500
Bilirubin Contraceptives, oral
“Irinogenetics” and UGT/A: from genotypes to haplotypes (Innocenti and Enhanced stimulant and metabolic effects of combined ephedrine and
Ratain). 2004;75:495-500 (Commentary) caffeine (Haller et al). 2004;75:259-73
UGTIAI haplotypes associated with reduced glucuronidation and in Corrections
creased serum bilirubin in irinotecan-administered Japanese patients Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxi
with cancer (Sai et al). 2004;75:501-15 dase, and cytochrome P450 2D6 are unaltered in children with cystic
Biological availability fibrosis (Kennedy et al) (2004;75:163-71). 2004;75:579
Orange juice substantially reduces the bioavailability of the B-adrenergic The effect of age, sex, and rifampin administration on intestinal and hepatic
blocking agent celiprolol (Lilja et al). 2004;75:184-90 cytochrome P450 3A activity (Gorski et al) (2003;74:275-87). 2004
St John’s wort decreases the bioavailability of R- and S-verapami! through 75:248-9
induction of the first-pass metabolism (Tannergren et al). 2004;75:298 Frequency of single nucleotide polymorphisms in the P-glycoprotein drus
309 transporter MDR/ gene in white subjects (Cascorbi et al)l (2001;69
Blood flow velocity 169-74). 2004:75:12
Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the Pharmacokinetics (PK) and pharmacodynamics (PD) of SCIO-469, a p38
rate of infusion (Sieber et al). 2004;75:70-9 gamma MAP kinase inhibitor (Amakye et al) (2004;75:P54). 2004;75
Body constitution 490
Contribution of age, body size, and CYP2C9 genotype to anticoagulant Correspondence; see Letters to the editor
response to warfarin (Kamali et al). 2004;75: Cyclooxygenases; see Prostaglandin-endoperoxide synthase
Books received Cyclosporine
Books received. 2004;75:369-70 CYP3AS5 and MDRI! genetic polymorphisms and cyclosporine pharmac«
Buprenorphine kinetics after renal transplantation (Anglicheau et al). 2004;75:422-33
Randomized trial of buprenorphine for treatment of concurrent opiate Cystic fibrosis
cocaine dependence (Montoya et al). 2004;75:34-48 Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine «
C dase, and cytochrome P450 2D6 are unaltered in children with cysti
fibrosis (Kennedy et al). 2004;75:163-71. Correction 2004;75:579
Caffeine Cytochrome P450
Enhanced stimulant and metabolic effects of combined ephedrine Acenocoumarol stabilization is delayed in CYP2C9*3 carriers (Schale
caffeine (Haller et al). 2004; kamp et al). 2004;75:394-402
‘alabresi, Paul Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxi
Paul Calabresi, 1930-2003 (Abernethy). 2004;75:250-1 (Obituary) dase, and cytochrome P450 2D6 are unaltered in children with cystic
‘anada fibrosis (Kennedy et al). 2004;75 rrection 2004;75:579
Folic acid and neuroblastoma: too soon to tell (Barone and Bunin) (Letter); ontribution of age, body size, and CYP2C9 genotype to anticoas
(Koren) (Reply). 2004; 5:489-90 response to warfarin (Kamali et al). 2004;75:204-12
‘ancer; see Neoplasms "YP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels
‘ardiac transplantation; see Heart transplantation (Katz et al). 2004;75:516-28
‘ardiopulmonary bypass YP3A5 genotype and midazolam clearance in Australian patients receiv
Changes in drug plasma concentrations of an extensively bound and highly ing chemotherapy (Wong et al). 2004;75:529-38
extracted drug, propofol, in response to altered plasma binding YP3A5 and MDR/ genetic polymorphisms and cyclosporine pharmaco
(Hiraoka et al). 2004;75:324-30 kinetics after renal transplantation (Anglicheau et al). 2004;75
‘ardiotonic agents YP2C9 genotypes and dose requirements during the induction phase of
Enhanced stimulant and metabolic effects of combined ephedrine and oral anticoagulant therapy (Peyvandi et al). 2004;75:198-2
caffeine (Haller et al). 2004;75 ‘°YP2C9 and oral anticoagulation therapy with acenocoumarol a1
Carvedilol rin: similarities yet differences (Takahashi et al). 2004;75:376-80
CYP2D6 genotype and induction of intestinal drug transporters by rifampin (Commentary )
predict presystemic clearance of carvedilol in healthy subjects (Giess- YP2D6 genotype: impact on adverse effects and nonresponse during
mann et al). 2004;75:213-22 treatment with antidepressants—a pilot study (Rau et al). 2004;75
Celiprolol 386-93
Orange juice substantially reduces the bioavailability of the B-adrenergic YP2D6 genotype and induction of intestinal drug transporters by rifampin
blocking agent celiprolol (Lilja et al). 2004;75:184-90 predict presystemic clearance of carvedilol in healthy subjects (Giess
Chemotherapy; see Drug therapy mann et al). 2004;75:213-22
Child ‘ytochrome P450 1A2 is a major determinant of lidocaine metabolism in
Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxi vivo: effects of liver function (Orlando et al). 2004;75:80-8
dase, and cytochrome P450 2D6 are unaltered in children with cystic ‘ytochrome P450 2D6 and antidepressant toxicity and response: what is
fibrosis (Kennedy et al). 2004;75:163-71. Correction 2004;75:579 the evidence? (Wedlund and de Leon). 2004;75:373-5 (Commentary)
Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and ‘ytochrome P450 3A4 and P-glycoprotein expression in human small
adolescent cardiac transplant recipients on a regimen of triple immu- intestinal enterocytes and hepatocytes: a comparative analysis in
nosuppression (Hedman et al). 2004;75:101-9 paired tissue specimens (von Richter et al). 2004;75:172-83
CLINICAL PHARMACOLOGY & THERAPEUTICS
598 Subject index
JUNE 2004
6°7°-Dihydroxybergamottin contributes to the grapefruit juice effect Use of population modeling to define rational monitoring of amiodarone
(Kakar et al). 2004;75:569-79 hepatic effects (Pollak and Shafer). 2004;75:342-51
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of Drug therapy
docetaxel (Engels et al). 2004;75:448-54 CYP3AS genotype and midazolam clearance in Australian patients receiv-
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 ing chemotherapy (Wong et al). 2004;75:529-38
activity in vivo (Gorski et al). 2004;75:89-100 Drugs
Human liver cytochrome P450 2D6 genotype, full-length messenger ribo- CYP2D6 genotype and induction of intestinal drug transporters by rifampin
nucleic acid, and activity assessed with a novel cytochrome P450 2D6 predict presystemic clearance of carvedilol in healihy subjects (Giess-
substrate (McConnachie et al). 2004;75:282-97 mann et al). 2004;75:213-22
Nelfinavir and felodipine: a cytochrome P450 3A4-—mediated drug inter- E
action (Izzedine et al). 2004;75:362-3 (Letter)
Pharmacogenetics of acenocoumarol pharmacodynamics (Morin et al) Echinacea; see Herbs
2004;75:403-14 Enfuvirtide
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic Assessment of drug-drug interaction potential of enfuvirtide in human
status (Ikeda et al). 2004;75:587-8 (Letter) immunodeficiency virus type l-infected patients (Zhang et al). 2004;
St John’s wort induces both cytochrome P450 3A4-—catalyzed sulfoxida 75:558-68
tion and 2C19-—dependent hydroxylation of omeprazole (Wang et al) Ephedrine
2004:75:191-7 Enhanced stimulant and metabolic effects of combined ephedrine and
caffeine (Haller et al). 2004;75:259-73
D Ethiny! estradiol
Death, sudden, cardiac The effect of isotretinoin on the pharmacokinetics and pharmacodynamics
of ethinyl estradiol and norethindrone (Hendrix et al). 2004;75:464-75
Cyclic antidepressants and the risk of sudden cardiac death (Ray et al)
2004;75:234-41 F
Dementia
Felodipine
Treatment of urinary incontinence with anticholinergics in patients taking
6°7’-Dihydroxybergamottin contributes to the grapefruit juice effect
cholinesterase inhibitors for dementia (Siegler and Reidenberg). 2004;
(Kakar et al). 2004;75:569-79
75:484-8
Nelfinavir and felodipine: a cytochrome P450 3A4—mediated drug inter.
Digoxin
Effect of St John’s wort dose and preparations on the pharmacokinetics of action (Izzedine et al). 2004;75:362-3 (Letter)
Fever
digoxin (Mueller et al). 2004;75:546-57
Simvastatin treatment for inflammatory attacks of the hyperimmunoglobu-
Dihydroxybergamottin
linemia D and periodic fever syndrome (Simon et al). 2004;75:47
6°7’-Dihydroxybergamottin contributes to the grapefruit juice effect
Fluoroquinolones; see Anti-infective agents, fluoroquinolone
(Kakar et al). 2004;75:569-79
Fluvoxamine
Dipyridamole
Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in
Glyburide inhibits dipyridamole-induced forearm vasodilation but not
vivo: effects of liver function (Orlando et al). 2004;75:80-8
adenosine-induced forearm vasodilation (Bijlstra et al). 2004;75:
Fluvoxamine drastically increases concentrations and effects of tizanidine:
147-56 a potentially hazardous interaction (Granfors et al). 2004;75:331-41
Docetaxel
Folic acid
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of
Folic acid and neuroblastoma: too soon to tell (Barone and Bunin) (Letter);
docetaxel (Engels et al). 2004;75:448-54 (Koren) (Reply). 2004;75:489-90
Dose-response relationship, drug
Forearm
CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels Glyburide inhibits dipyridamole-induced forearm vasodilation but not
(Katz et al). 2004;75:516-28
adenosine-induced forearm vasodilation (Bijlstra et al). 2004;75:
Pharmacokinetic studies in hepatic impairment: is the Maddrey function a
relevant marker? (Gardmark et al). 2004;75:586-7 (Letter) 147 56
Drug interactions G
Assessment of drug-drug interaction potential of enfuvirtide in human Gemfibrozil
immunodeficiency virus type |-infected patients (Zhang et al). 2004; The effect of gemfibrozil on the pharmacokinetics of rosuvastatin (Schneck
75:558-68 et al). 2004;75:455-63
Drug interactions with herbal products and grapefruit juice: a conference Genes
report (Huang et al). 2004;75:1-12 (Commentary) CYP3AS5 and MDRI genetic polymorphisms and cyclosporine pharmaco-
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin (Schneck kinetics after renal transplantation (Anglicheau et al). 2004;75:422-33
et al). 2004;75:455-63 Polymorphisms in human MDR/ (P-glycoprotein): recent advances and
The effect of isotretinoin on the pharmacokinetics and pharmacodynamics clinical relevance (Marzolini et al). 2004;75:13-33
of ethinyl estradiol and norethindrone (Hendrix et al). 2004;75:464-75 Genetics
Enhanced stimulant and metabolic effects of combined ephedrine and 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)
caffeine (Haller et al). 20( and genetic variability (single nucleotide polymorphisms) in a hepatic
Fluvoxamine drastically increases concentrations and effects of tizanidine drug uptake transporter: what’s it all about? (Kim). 2004;75:381-5
tentially hazardous interaction (Granfors et al). 2004;75:331-41 (Commentary)
Interactions between amprenavir and the lopinavir-ritonavir combination in Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic
heavily pretreated patients infected with human immunodeficiency status (Ikeda et al). 2004;75:587-8 (Letter)
virus (Taburet et al). 2004;75:310-23 Genotype
Nelfinavir and felodipine: a cytochrome P450 3A4-—mediated drug inter Contribution of age, body size, and CYP2C9 genotype to anticoagulant
action (Izzedine et al). 2004;75:362-3 (Letter) response to warfarin (Kamali et al). 2004;75:204-12
Tramadol pharmacokinetics and its possible interactions with cyclooxy- CYP2C9 genotypes and dose requirements during the induction phase of
genase 2-selective nonsteroidal anti-inflammatory drugs (Punwani) oral anticoagulant therapy (Peyvandi et al). 2004;75:198-203
2004;75:363-5 (Letter) CYP2D6 genotype: impact on adverse effects and nonresponse during
Drug monitoring treatment with antidepressants—a pilot study (Rau et al). 2004;75:
Monitoring amiodarone’s toxicities: recommendations, evidence, and clin 386-93
ical practice (Stelfox et al). 2004;75:110-22 CYP2D6 genotype and induction of intestinal drug transporters by rifampin
CLINICAL PHARMACOLOGY & THERAPEUTICS
Subject index 599
2004;75(6):596-602
predict presystemic clearance of carvedilol in healthy subjects (Giess- immunodeficiency virus type l—infected patients (Zhang et al). 2004;
mann et al). 2004;75:213-22 75:558-68
CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels Hydroxylation
(Katz et al). 2004;75:516-28 St John’s wort induces both cytochrome P450 3A4—catalyzed sulfoxida-
CYP3AS5 genotype and midazolam clearance in Australian patients receiv- tion and 2C19—dependent hydroxylation of omeprazole (Wang et al)
ing chemotherapy (Wong et al). 2004;75:529-38 2004;75:191-7
Human liver cytochrome P450 2D6 genotype, full-length messenger ribo- Hyperimmunoglobulinemia
nucleic acid, and activity assessed with a novel cytochrome P450 2D6 Simvastatin treatment for inflammatory attacks of the hyperimmunoglobu-
substrate (McConnachie et al). 2004;75:282-97 linemia D and periodic fever syndrome (Simon et al). 2004;75:476-83
“Irinogenetics” and UGT/A: from genotypes to haplotypes (Innocenti and Hypoglycemic agents
Ratain). 2004;75:495-500 (Commentary) Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy
UGTIAI haplotypes associated with reduced glucuronidation and in- subjects (Park et al). 2004;75:157-62
creased serum bilirubin in irinotecan-administered Japanese patients
with cancer (Sai et al). 2004;75:S01-1
Glucuronosyltransferase Immunosuppression
“Irinogenetics” and UGT/A: from genotypes to haplotypes (Innocenti and Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and
Ratain). 2004;75:495-500 (Commentary) adolescent cardiac transplant recipients on a regimen of triple immu
A novel functional polymorphism in the uridine diphosphate— glucurono- nosuppression (Hedman et al). 2004;75:101-9
syltransferase 2B7 promoter with significant impact on promoter ac Inflammation
tivity (Duguay et al). 2004;75:223-33 Simvastatin treatment for inflammatory attacks of the hyperimmunoglobu-
UGTIAI haplotypes associated with reduced glucuronidation and in- linemia D and periodic fever syndrome (Simon et al). 2004;75:476-83
creased serum bilirubin in irinotecan-administered Japanese patients Infusions, intravenous
with cancer (Sai et al). 2004;75:501-15 Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the
Glyburide rate of infusion (Sieber et al). 2004;75:70-9
Glyburide inhibits dipyridamole-induced forearm vasodilation but not Interactions, drug; see Drug interactions
Intestine, small
adenosine-induced forearm vasodilation (Bijlstra et al). 2004;75:
147-56 Cytochrome P450 3A4 and P-glycoprotein expression in human small
Glycoproteins intestinal enterucytes and hepatocytes: a comparative analysis in
Cytochrome P450 3A4 and P-glycoprotein expression in human small paired tissue specimens (von Richter et al). 2004;75:172-83
intestinal enterocytes and hepatocytes: a comparative analysis in Tacrolimus therapy according to mucosal MDRI levels in small-bowel
transplant recipients (Masuda et al). 2004;75:352-61
paired tissue specimens (von Richter et al). 2004;75:172-83
Intestines
Polymorphisms in human MDR/ (P-glycoprotein): recent advances and
CYP2D6 genotype and induction of intestinal drug transporters by rifampin
clinical relevance (Marzolini et al). 2004;75:13-33
predict presystemic clearance of carvedilol in healthy subjects (Giess-
Grapefruit juice; see Beverages
mann et al). 2004;75:213-22
Guest reviewers
Irinotecan
Guest reviewers. 2004;75:366-8
“Irinogenetics” and UGTIA: from genotypes to haplotypes (Innocenti and
H Ratain). 2004;75:495-500 (Commentary)
GTIAI haplotypes associated with reduced glucuronidation and in-
Haplotypes creased serum bilirubin in irinotecan-administered Japanese patients
Evidence for inverse effects of OATP-C (SLC21A6) *5 and */b haplotypes with cancer (Sai et al). 2004;75:501-15
on pravastatin kinetics (Mwinyi et al). 2004;75:415-21 Isoproterenol
“Irinogenetics” and UGT/A: from genotypes to haplotypes (Innocenti and Mechanisms of B-adrenergic receptor—mediated venodilation in humans
Ratain). 2004;75:495-500 (Commentary) (Schindler et al). 2004;75:49-59
UGTIAI haplotypes associated with reduced glucuronidation and in- Isotretinoin
creased serum bilirubin in irinotecan-administered Japanese patients The effect of isotretinoin on the pharmacokinetics and pharmacodynamics
with cancer (Sai et al). 2004;75:501-15 of ethiny! estradiol and norethindrone (Hendrix et al). 2004;75:464-75
Heart transplantation
Pharmacokinetics and pharmacodynamics of pravastetin in pediatric and J
adolescent cardiac transplant recipients on a regiinen of triple immu- Japan
nosuppression (Hedman et al). 2004;75:101-9 ‘Irinogenetics” and UGTIA: from genotypes to haplotypes (Innocenti and
Hemoglobin, sickle Ratain). 2004;75:495-500 (Commentary)
Aspartame has no effect on the polymerization of sickle hemoglobin UGTIAI haplotypes associated with reduced glucuronidation and in-
(Rotter et al). 2004;75:248-9 (Letter) creased serum bilirubin in irinotecan-administered Japanese patients
Systemic exposure to morphine and the risk of acute chest syndrome in with cancer (Sai et al). 2004;75:501-15
sickle cell disease (Kopecky et al). 2004;75:140-6
Hepatic effects; see Liver K
Herbs Kidney transplantation
Drug interactions with herbal products and grapefruit juice: a conference Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid
report (Huang et al). 2004;75:1-12 (Commentary) in relation to combined long-term pharmacokinetics in de novo renal
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 allograft recipients (Kuypers et al). 2004;75:434-47
activity in vivo (Gorski et al). 2004;75:89-100 CYP3AS5 and MDRI genetic polymorphisms and cyclosporine pharmaco-
St John’s wort induces both cytochrome P450 3A4—catalyzed sulfoxida- kinetics after renal transplantation (Anglicheau et al). 2004;75:422-3
tion and 2C19-—dependent hydroxylation of omeprazole (Wang et al) Kinetics
2004;75:191-7 Evidence for inverse effects of OATP-C (SLC21]A6) *5 and */b haplotypes
HIV on pravastatin kinetics (Mwinyi et al). 2004;75:415-21
Interactions between amprenavir and the lopinavir-ritonavir combination in
heavily pretreated patients infected with human immunodeficiency
virus (Taburet et al). 2004;75:310-23 Lanreotide
HIV-1 Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the
Assessment of drug-drug interaction potential of enfuvirtide in human rate of infusion (Sieber et al). 2004;75:70-9
CLINICAL PHARMACOLOGY & THERAPEUTICS
600 Subject index
JUNE 2004
Leflunomide induction of the first-pass metabolism (Tannergren et al). 2004;75:298-
Peripheral neuropathy in patients treated with leflunomide (Bonnel and 309
Graham). 2004;75:580-5 Methylation
Postmarketing surveillance for drug safety: surely we can do better (Griffin Methylated metabolites of 6-mercaptopurine are associated with hepato-
et al). 2004;75:491-4 (Commentary) toxicity (Nygaard et al). 2004;75:274-81
Letters to the Editor Midazolam
Aspartame has no effect on the polymerization of sickle hemoglobin CYP3AS genotype and midazolam clearance in Australian patients receiv-
(Rotter et al). 2004;75:248-9 (Letter) ing chemotherapy (Wong et al). 2004;75:529-38
Do data presented at an American Society for Clinical Pharmacology and Monitoring, drug; see Drug monitoring
Therapeutics meeting make it to full publication? (Riessland et al). Morphine
2004;75:123-4 (Letter) A novel functional polymorphism in the uridine diphosphate— glucurono-
Folic acid and neuroblastoma: too soon to tell (Barone and Bunin) (Letter); syltransferase 2B7 promoter with significant impact on promoter ac-
(Koren) (Reply). 2004;75:489-90 tivity (Duguay et al). 2004;75:223-33
Nelfinavir and felodipine: a cytochrome P450 3A4—mediated drug inter- Systemic exposure to morphine and the risk of acute chest syndrome in
action (Izzedine et al). 2004;75:362-3 (Letter) sickle cell disease (Kopecky et al). 2004;75:140-6
Pharmacokinetic studies in hepatic impairment: is the Maddrey function a Mycophenolic acid
relevant marker? (Gardmark et al). 2004;75:586-7 (Letter) Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic in relation to combined long-term pharmacokinetics in de novo renal
status (Ikeda et al). 2004;75:587-8 (Letter) allograft recipients (Kuypers et al). 2004;75:434-47
Tramadol pharmacokinetics and its possible interactions with cyclooxy-
N
genase 2-selective nonsteroidal anti-inflammatory drugs (Punwani).
2004;75:363-5 (Letter) Narcotic dependence
Lidocaine Randomized trial of buprenorphine for treatment of concurrent opiate and
Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in cocaine dependence (Montoya et al). 2004;75:34-48
vivo: effects of liver function (Orlando et al). 2004;75:80-8 Nelfinavir
Liver Nelfinavir and felodipine: a cytochrome P450 3A4—mediated drug inter-
Cytochrome P450 3A4 and P-glycoprotein expression in human small action (Izzedine et al). 2004;75:362-3 (Letter)
intestinal enterocytes and hepatocytes: a comparative analysis in Neoplasms
paired tissue specimens (von Richter et al). 2004;75:172-83 “Irinogenetics” and UGT/A: from genotypes to haplotypes (Innocenti and
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin (Schneck Ratain). 2004;75:495-500 (Commentary)
et al). 2004;75:455-63 A novel functional polymorphism in the uridine diphosphate— glucurono-
Human liver cytochrome P450 2D6 genotype, full-length messenger ribo- syltransferase 2B7 promoter with significant impact on promoter ac-
nucleic acid, and activity assessed with a novel cytochrome P450 2D6 tivity (Duguay et al). 2004;75:223-33
substrate (McConnachie et al). 2004;75:282-97 UGTIAI haplotypes associated with reduced glucuronidation and in-
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) creased serum bilirubin in irinotecan-administered Japanese patients
and genetic variability (single nucleotide polymorphisms) in a hepatic with cancer (Sai et al). 2004;75:501-15
drug uptake transporter: what’s it all about? (Kim). 2004;75:381-5 Nerve net
(Commentary) Abciximab pharmacodynamic model with neural networks used to inte-
Methylated metabolites of 6-mercaptopurine are associated with hepato- grate sources of patient variability (Urquidi-Macdonald et al). 2004:
toxicity (Nygaard et al). 2004;75:274-81 75:60-9
Use of population modeling to define rational monitoring of amiodarone Nervous system neoplasms
hepatic effects (Pollak and Shafer). 2004;75:342-51 Folic acid and neuroblastoma: too soon to tell (Barone and Bunin) (Letter);
Liver function tests (Koren) (Reply). 2004;75:489-90
Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in Netherlands
vivo: effects of liver function (Orlando et al). 2004;75:80-8 Acenocoumarol stabilization is delayed in CYP2C9*3 carriers (Schale-
Pharmacokinetic studies in hepatic impairment: is the Maddrey function a kamp et al). 2004;75:394-402
relevant marker? (Gardmark et al). 2004;75:586-7 (Letter) Neuroblastoma
Lopinavir Folic acid and neuroblastoma: too soon to tell (Barone and Bunin) (Letter);
Interactions between amprenavir and the lopinavir-ritonavir combination in (Koren) (Reply). 2004;75:489-90
heavily pretreated patients infected with human immunodeficiency Neuropathy
virus (Taburet et al). 2004;75:310-23 Peripheral neuropathy in patients treated with leflunomide (Bonnel and
Graham). 2004;75:580-5
M
Postmarketing surveillance for drug safety: surely we can do better (Griffin
MDR1 gene; see Getes et al). 2004;75:491-4 (Commentary)
MDRI protein; see Proteins Non-steroidal anti-inflammatory drugs; see Anti-inflammatory agents,
Medicine, herbal non-steroidal
Effect of St John’s wort dose and preparations on the pharmacokinetics of Norethindrone
digoxin (Mueller et al). 2004;75:546-57 The effect of isotretinoin on the pharmacokinetics and pharmacodynamics
St John’s wort decreases the bioavailability of R- and S-verapamil through of ethinyl estradiol and norethindrone (Hendrix et al). 2004;75:464-75
induction oft he first-pass metabolism (Tannergren et al). 2004;75:298 Nucleotides
309 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins)
Mercaptopurine and genetic variability (single nucleotide polymorphisms) in a hepatic
Methylated metabolites of 6-mercaptopurine are associated with hepato- drug uptake transporter: what’s it all about? (Kim). 2004;75:381-5
toxicity (Nygaard et al). 2004;75:274-81 (Commentary)
Messenger RNA; see RNA, messenger
O
Metabolism
Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in OATP-C; see Anions; Peptides
vivo: effects of liver function (Orlando et al). 2004;75:80-8 Obituary
Enhanced stimulant and metabolic effects of combined ephedrine and Paul Calabresi, 1930-2003 (Abernethy). 2004;75:250-1
caffeine (Haller et al). 2004;75:259-73 Omeprazole
St John’s wort decreases the bioavailability of R- and S-verapamil through St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxida-